Overall survival (OS) results of phase III ARAMIS study of darolutamide added to androgen deprivation therapy (ADT) for non-metastatic castration-resistant prostate cancer (nmCRPC)

被引：0
|
作者：
Krieger, Laurence [1 ]
Fizazi, Karim [2 ]
Shore, Neal [3 ]
Tammela, Teuvo L. [4 ,5 ]
Ulys, Albertas [6 ]
Vjaters, Egils [7 ]
Polyakov, Sergey [8 ]
Jievaltas, Mindaugas [9 ]
Luz, Murilo [10 ]
Alekseev, Boris [11 ]
Kuss, Iris [12 ]
Le Berre, Marie-Aude [13 ]
Petrenciuc, Oana [14 ]
Snapir, Amir [15 ]
Sarapohja, Toni [15 ]
Smith, Matthew R. [16 ]
机构：
[1] Northern Canc Inst, St Leonards, NSW, Australia
[2] Univ Paris Sud, Inst Gustave Roussy, Paris, France
[3] Carolina Urol Res Ctr, Myrtle Beach, SC USA
[4] Tampere Univ Hosp, Tampere, Finland
[5] Tampere Univ, Tampere, Finland
[6] NCI, Bethesda, MD 20892 USA
[7] Stradins Clin Univ Hosp, Riga, Latvia
[8] NN Alexandrov Natl Canc Ctr Belarus, Liasny, BELARUS
[9] Lithuanian Univ Hlth Sci, Med Acad, Kaunas, Lithuania
[10] Hosp Erasto Gaertner, Curitiba, Parana, Brazil
[11] Minist Hlth Russian Federat, Natl Med Res Radiol Ctr, Moscow, Russia
[12] Bayer AG, Leverkusen, Germany
[13] Bayer Healthcare SAS, Leverkusen, Germany
[14] Bayer Healthcare, Leverkusen, Germany
[15] Orion Corp Orion Pharma, Espoo, Finland
[16] Massachusetts Gen Hosp, Canc Ctr, Boston, MA 02114 USA
来源：
ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY | 2020年 / 16卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
abs27
引用
收藏
页码：45 / 46
页数：2
相关论文
共 50 条
  • [41] Apalutamide (APA) and Overall Survival (OS) in Patients (PTS) with Nonmetastatic Castration-Resistant Prostate Cancer (NMCRPC): Updated Results from The Phase 3 Spartan Study
    Hadaschik, Boris A.
    Smith, Matthew R.
    Saad, Fred
    Chowdhury, Simon
    Oudards, Stephane
    Graff, Julie N.
    Olmos, David
    Mainwaring, Paul N.
    Lee, Ji Youl
    Uemura, Hiroji
    De Porre, Peter
    Smith, Andressa
    Zhang, Ke
    Lopez-Gitlitz, Angela
    Small, Eric J.
    ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 : 71 - 71
  • [42] Physician benefit-risk preferences for non-metastatic castration-resistant prostate cancer treatment (nmCRPC).
    Srinivas, Sandy
    Mohamed, Ateesha F.
    Appukkuttan, Sreevalsa
    Botteman, Marc
    Ng, Xinyi
    Joshi, Namita
    Horodniceanu, Erica
    Waldeck, Reg
    Simmons, Stacey J.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [43] TREATMENT DURATION AND LONG-TERM SAFETY AND TOLERABILITY WITH DAROLUTAMIDE IN NONMETASTATIC CASTRATION-RESISTANT PROSTATE CANCER (NMCRPC): ARAMIS ROLLOVER STUDY
    Shore, Neal D.
    Luz, Murilo
    Ulys, Albertas
    Ortiz, Jorge
    Srinivasan, Shankar
    Kurland, Etah
    Fizazi, Karim
    JOURNAL OF UROLOGY, 2023, 209 : E129 - E130
  • [44] Safety, tolerability, and duration of continued darolutamide treatment in patients with nonmetastatic castration-resistant prostate cancer (nmCRPC): ARAMIS Rollover Study (ROS)
    Fizazi, K.
    Luz, M.
    Ulys, A.
    Ortiz, J.
    Srinivasan, S.
    Kurland, E.
    Shore, N. D.
    EUROPEAN UROLOGY, 2023, 83
  • [45] Conceptual assessment of HRQOL among Japanese non-metastatic castration-resistant prostate cancer (nmCRPC) patients
    Nishimura, Kazuo
    Shiota, Masaki
    Eto, Masatoshi
    Satoh, Takefumi
    Stroupe, Angela
    Seo, Caroline
    Uzumcu, Alyssa
    Ledesma, Dianne Athene
    CANCER MEDICINE, 2023, 12 (02): : 1762 - 1778
  • [46] Androgen receptor axis-targeted agents for non-metastatic castration-resistant prostate cancer impact on overall survival and safety profile
    Mori, Keiichiro
    Quhal, Fahad
    Katayama, Satoshi
    Mostafaei, Hadi
    Laukhtina, Ekaterina
    Schuettfort, Victor M.
    Sari Motlagh, Reza
    Grossmann, Nico C.
    Rajwa, Pawel
    Ploussard, Guillaume
    Briganti, Alberto
    Kimura, Takahiro
    Egawa, Shin
    Papalia, Rocco
    Carrion, Diego M.
    Fiori, Cristian
    Shariat, Shahrokh F.
    Esperto, Francesco
    Pradere, Benjamin
    MINERVA UROLOGY AND NEPHROLOGY, 2022, 74 (03): : 292 - 301
  • [47] ARAMIS trial: Efficacy and safety phase 3 trial of ODM-201 in men with high-risk non-metastatic castration-resistant prostate cancer (nmCRPC).
    Fizazi, Karim
    Shore, Neal D.
    Tammela, Teuvo L. J.
    Sarapohja, Toni
    Vuorela, Annamari
    Kuss, Iris
    Snapir, Amir
    Smith, Matthew Raymond
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [48] Darolutamide: A Review in Non-Metastatic Castration-Resistant Prostate Cancer (vol 15, pg 791, 2020)
    Scott, Lesley J.
    TARGETED ONCOLOGY, 2022, 17 (03) : 381 - 381
  • [49] Health-related quality of life (HRQoL) at final analysis of the SPARTAN study of apalutamide (APA) vs placebo (PBO) in patients (pts) with non-metastatic castration-resistant prostate cancer (nmCRPC) receiving androgen deprivation therapy (ADT)
    Oudard, S.
    Hadaschik, B. A.
    Saad, F.
    Cella, D.
    Basch, E.
    Mainwaring, P. N.
    Graff, J. N.
    Dibaj, S.
    Li, S.
    Brookman-May, S. D.
    De Porre, P.
    Trudeau, J. J.
    Small, E. J.
    Smith, M. R.
    ANNALS OF ONCOLOGY, 2020, 31 : S521 - S521
  • [50] International survey of androgen deprivation therapy (ADT) for non-metastatic prostate cancer in 19 countries
    Liede, Alexander
    Hallett, David C.
    Hope, Kirsty
    Graham, Alex
    Arellano, Jorge
    Shahinian, Vahakn B.
    ESMO OPEN, 2016, 1 (02)
12345